This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

SciClone: Pump Up the Volume

FOSTER CITY, Calif. ( TheStreet) -- SciClone Pharmaceuticals (SCLN - Get Report) was trading sharply lower on a jump in volume after the company said it ended a clinical trial of its late-stage pancreatic cancer drug treatment.

SciClone late Friday said it discontinued a placebo-controlled, double-blind Phase 2 trial of its RP101 drug candidate for the treatment of late-stage pancreatic cancer. The company said the decision to end the trial came on the recommendation of the Data Safety Monitoring Committee.

RP101, also known as BvdU, is a nucleoside analog which has shown, in several preclinical and clinical studies, the potential to prevent the induction of resistance to chemotherapy by suppressing genes involved in development of that resistance and enhancing sensitivity to chemotherapy, SciClone said in its statement.

SciClone shares were sinking on big volume. The stock was lately falling 63 cents, or 15.2%, to $$3.52, making it one of the Nasdaq's worst performers Monday. Earlier in the session, the stock touched an intraday low of $3.31.

More than 1.5 million shares changed hands by 2 p.m. Monday, compared to the stock's 50-day average daily volume of 700,000, according to the Nasdaq. SciClone has a 35.7 million-share float with a short interest float of 3.2% as of Sept. 10, according to Yahoo! Finance. More than 37% of the company's shares are held by insiders with another 15% owned by institutions.

Some investor posts on Internet message boards argued that despite SciClone's setback with RP101, the company has more prospects in the pipeline. Other traders said that SciClone has seen too many trials fail outside of China.

Read more about today's high-volume stocks like Frontier Financial in earlier "Pump Up the Volume" posts.

-- Written by Robert Holmes in New York.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
SCLN $8.07 0.00%
AAPL $94.99 0.00%
FB $99.54 0.00%
GOOG $678.11 0.00%
TSLA $148.25 0.00%


Chart of I:DJI
DOW 16,014.38 -12.67 -0.08%
S&P 500 1,852.21 -1.23 -0.07%
NASDAQ 4,268.7630 -14.99 -0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs